IL157940A0 - Drugs containing triazaspiro [5.5] undecane derivatives as the active ingredient - Google Patents

Drugs containing triazaspiro [5.5] undecane derivatives as the active ingredient

Info

Publication number
IL157940A0
IL157940A0 IL15794002A IL15794002A IL157940A0 IL 157940 A0 IL157940 A0 IL 157940A0 IL 15794002 A IL15794002 A IL 15794002A IL 15794002 A IL15794002 A IL 15794002A IL 157940 A0 IL157940 A0 IL 157940A0
Authority
IL
Israel
Prior art keywords
triazaspiro
active ingredient
drugs containing
undecane derivatives
undecane
Prior art date
Application number
IL15794002A
Other languages
English (en)
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of IL157940A0 publication Critical patent/IL157940A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15794002A 2001-03-19 2002-03-18 Drugs containing triazaspiro [5.5] undecane derivatives as the active ingredient IL157940A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001079611 2001-03-19
PCT/JP2002/002553 WO2002074769A1 (fr) 2001-03-19 2002-03-18 Medicaments contenant comme principe actif des derives du triazaspiro [5.5] undecane

Publications (1)

Publication Number Publication Date
IL157940A0 true IL157940A0 (en) 2004-03-28

Family

ID=18936022

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15794002A IL157940A0 (en) 2001-03-19 2002-03-18 Drugs containing triazaspiro [5.5] undecane derivatives as the active ingredient

Country Status (17)

Country Link
US (1) US7285552B2 (cs)
EP (1) EP1378509A4 (cs)
JP (1) JPWO2002074769A1 (cs)
KR (1) KR20030093248A (cs)
CN (1) CN1533390A (cs)
BR (1) BR0208229A (cs)
CA (1) CA2441162A1 (cs)
CZ (1) CZ20032532A3 (cs)
HU (1) HUP0400241A2 (cs)
IL (1) IL157940A0 (cs)
MX (1) MXPA03008528A (cs)
NO (1) NO20034149L (cs)
NZ (1) NZ528270A (cs)
PL (1) PL364469A1 (cs)
RU (1) RU2003128075A (cs)
WO (1) WO2002074769A1 (cs)
ZA (1) ZA200307318B (cs)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100714154B1 (ko) 2001-03-19 2007-05-07 오노 야꾸힝 고교 가부시키가이샤 트리아자스피로[5.5]운데칸 유도체 및 이들을유효성분으로 하는 약제
TW200413372A (en) * 2002-09-18 2004-08-01 Ono Pharmaceutical Co Derivatives of triazaspiro [5.5] undecane and medicants using such derivatives as effective ingredient
US7361758B2 (en) 2002-09-18 2008-04-22 Ono Pharmaceutical Co., Ltd. Crystals of triazaspiro[5.5]undecane derivative
US20060251651A1 (en) * 2002-12-13 2006-11-09 Ono Pharmaceutical Co., Ltd. Antagonist and agonist which bind to a strong binding site of chemokine receptor
EP1621540A4 (en) * 2003-04-21 2008-07-23 Ono Pharmaceutical Co HETEROCYCLIC COMPOUNDS CONTAINING NITROGEN AND USE THEREOF
JP5135795B2 (ja) * 2004-08-27 2013-02-06 小野薬品工業株式会社 塩基性基を含有する化合物およびその用途
WO2006060177A1 (en) * 2004-12-01 2006-06-08 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gw873140
WO2010009196A1 (en) * 2008-07-15 2010-01-21 Temple University Of The Commonwealth System Of Higher Education Synthesis of bis-peptides oligomers comprising at least one n-substituted diketopiperazine as structural moiety
JP2011530562A (ja) 2008-08-11 2011-12-22 グラクソスミスクライン エルエルシー アレルギー性、炎症性及び感染性疾患治療用のプリン誘導体
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
LT2320905T (lt) 2008-08-11 2017-09-11 Glaxosmithkline Llc Naujieji adenino dariniai
US8575340B2 (en) 2010-02-10 2013-11-05 Glaxosmithkline Llc Purine derivatives and their pharmaceutical uses
CA2786973C (en) 2010-02-10 2018-04-10 Robert Hermann Gibbon 6-amino-2-{[(1s)-1-methylbutyl] oxy}-9-[5-(1-piperidinyl)-7,9-dihydro-8h-purin-8-one maleate
LT2624696T (lt) 2010-10-06 2017-03-10 Glaxosmithkline Llc Benzimidazolo deriniai kaip pi3 kinazės inhibitoriai
JP6055468B2 (ja) 2011-07-15 2016-12-27 ヴィーブ ヘルスケア ユーケー リミテッド アザインドール化合物及びｈｉｖを治療するための方法
WO2013043553A1 (en) 2011-09-22 2013-03-28 Glaxosmithkline Llc Pyrrolopyridinone compounds and methods for treating hiv
JO3387B1 (ar) 2011-12-16 2019-03-13 Glaxosmithkline Llc مشتقات بيتولين
JP6129962B2 (ja) 2012-07-12 2017-05-17 ヴィーブ ヘルスケア ユーケー リミテッド 化合物及びｈｉｖを治療するための方法
JP6452711B2 (ja) 2014-02-20 2019-01-16 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ ヒトインターフェロンの誘導物質としてのピロロ［３，２］ピリミジン誘導体
CA2967248A1 (en) 2014-11-13 2016-05-19 Glaxosmithkline Biologicals Sa Adenine derivatives which are useful in the treatment of allergic diseases or other inflammatory conditions
TW201708210A (zh) 2015-06-30 2017-03-01 葛蘭素史克智慧財產（第二）有限公司 Ｚｅｓｔｅ同源物２增強子之抑制劑
EP3317287B1 (en) 2015-07-02 2019-07-31 GlaxoSmithKline Intellectual Property Development Limited Inhibitors of indoleamine 2,3-dioxygenase
JP2018521093A (ja) 2015-07-28 2018-08-02 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ Ｈｉｖ感染を予防または治療するためのベツイン誘導体
RU2018105352A (ru) 2015-07-28 2019-08-29 ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед Производные бетулина для предупреждения или лечения ВИЧ-инфекций
KR20180054826A (ko) 2015-09-24 2018-05-24 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 Hiv 성숙 억제 활성을 갖는 화합물
EP3366691A1 (en) 2015-12-03 2018-08-29 GlaxoSmithKline Intellectual Property Development Limited Cyclic purine dinucleotides as modulators of sting
WO2017130156A1 (en) 2016-01-27 2017-08-03 Glaxosmithkline Intellectual Property (No.2) Limited Ingenol analogs, pharmaceutical compositions and methods of use thereof
CA3019628A1 (en) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
KR102527786B1 (ko) 2016-04-07 2023-04-28 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 단백질 조정제로서 유용한 헤테로시클릭 아미드
JP2019516685A (ja) 2016-05-05 2019-06-20 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ Ｚｅｓｔｅホモログ２阻害剤のエンハンサー
WO2018002902A1 (en) 2016-07-01 2018-01-04 Glaxosmithkline Intellectual Property (No.2) Limited Antibody-drug conjugates and therapeutic methods using the same
WO2018083087A2 (en) 2016-11-02 2018-05-11 Glaxosmithkline Intellectual Property (No.2) Limited Binding proteins
UY37710A (es) 2017-05-02 2018-11-30 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
WO2019069270A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited GENERATOR STIMULATOR MODULATORS (STING) INTERFERON
TW201927771A (zh) 2017-10-05 2019-07-16 英商葛蘭素史密斯克藍智慧財產發展有限公司 可作為蛋白質調節劑之雜環醯胺及其使用方法
US11274102B2 (en) 2017-10-30 2022-03-15 Glaxosmithkline Intellectual Property Development Limited Compounds useful in HIV therapy
EP3762396A1 (en) 2018-03-07 2021-01-13 GlaxoSmithKline Intellectual Property (No.2) Limited Compounds useful in hiv therapy
US11505543B2 (en) 2018-04-11 2022-11-22 VIIV Healthcare UK (No.5) Limited 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
JP2021534112A (ja) 2018-08-09 2021-12-09 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited Ｈｉｖ療法に有用な化合物
JP2021536444A (ja) 2018-08-30 2021-12-27 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited Ｈｉｖ療法に有用な化合物
AR117206A1 (es) 2018-11-30 2021-07-21 Glaxosmithkline Ip Dev Ltd Derivados de octahidropirrolo[2,1-b][1,3]tiazepin-7-carboxamido útiles en la terapia para el vih y para el tratamiento del cáncer
JP2022525013A (ja) 2019-03-06 2022-05-11 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッド Ｈｉｖ療法において有用な化合物
US20220227761A1 (en) 2019-05-16 2022-07-21 Stingthera, Inc. Oxoacridinyl acetic acid derivatives and methods of use
EP3969452A1 (en) 2019-05-16 2022-03-23 Stingthera, Inc. Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
JP2022543319A (ja) 2019-08-08 2022-10-11 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッド Ｈｉｖ治療に有用な化合物
WO2021038509A1 (en) 2019-08-28 2021-03-04 Glaxosmithkline Intellectual Property (No.2) Limited 4'-ethynyl-2'-deoxyadenosine derivatives and their use in hiv therapy
US20240182510A1 (en) 2021-02-23 2024-06-06 Viiv Healthcare Company Compounds Useful in HIV Treatment
AR129423A1 (es) 2022-05-27 2024-08-21 Viiv Healthcare Co Compuestos útiles en la terapia contra el hiv

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS231227B1 (en) 1982-10-01 1984-10-15 Evzen Kasafirek 2,5-pierazindion derivatives
WO1993013101A1 (en) * 1991-12-27 1993-07-08 Yoshitomi Pharmaceutical Industries, Ltd. Pyridonecarboxylate compound, pharmaceutical use thereof, and spiro compound
US6291469B1 (en) 1995-09-29 2001-09-18 Eli Lilly And Company Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
US6288083B1 (en) * 1998-09-04 2001-09-11 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
ATE283854T1 (de) 1999-12-03 2004-12-15 Ono Pharmaceutical Co Triazaspiro(5.5)undecan-derivate und drogen, die dasselbe als aktiven inhaltsstoff enthalten
FR2804882B1 (fr) 2000-02-11 2002-05-10 Air Liquide Procede de compression d'air atmospherique
KR100714154B1 (ko) 2001-03-19 2007-05-07 오노 야꾸힝 고교 가부시키가이샤 트리아자스피로[5.5]운데칸 유도체 및 이들을유효성분으로 하는 약제

Also Published As

Publication number Publication date
US20040106619A1 (en) 2004-06-03
BR0208229A (pt) 2004-03-09
ZA200307318B (en) 2004-07-29
KR20030093248A (ko) 2003-12-06
RU2003128075A (ru) 2005-04-10
NZ528270A (en) 2005-10-28
MXPA03008528A (es) 2004-06-30
EP1378509A1 (en) 2004-01-07
WO2002074769A1 (fr) 2002-09-26
CZ20032532A3 (en) 2004-03-17
US7285552B2 (en) 2007-10-23
JPWO2002074769A1 (ja) 2004-07-08
PL364469A1 (en) 2004-12-13
EP1378509A4 (en) 2009-03-25
NO20034149D0 (no) 2003-09-17
NO20034149L (no) 2003-11-19
HUP0400241A2 (hu) 2004-06-28
CA2441162A1 (en) 2002-09-26
CN1533390A (zh) 2004-09-29

Similar Documents

Publication Publication Date Title
IL157940A0 (en) Drugs containing triazaspiro [5.5] undecane derivatives as the active ingredient
PL376154A1 (en) Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient
AU2002238947A1 (en) Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient
IL161940A0 (en) Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient
HUP0204170A3 (en) 5-thia-omega-substituted phenyl-prostaglandin e derivatives, process for producing the same and drugs containing the same as the active ingredient
IL160707A0 (en) 1, 8-naphthyridine derivatives as antidiabetics
AU3076700A (en) 2h-phthalazin-1-one derivatives and drugs comprising these derivatives as the active ingredient
MXPA03006884A (es) Formulacion farmaceutica.
AU2002226674A1 (en) Tricyclic and heterocyclic derivative compounds and drugs containing these compounds as the active ingredient
MXPA03007641A (es) Formulacion farmaceutica.
HK1042245A1 (en) Pharmaceutical moxifloxacin preparation.
AU2002354054A1 (en) Spiroheterocyclic derivative compounds and drugs comprising the compounds as the active ingredient
IL156536A0 (en) Pyrazolo [3,4-d] pyrimidin-4-one derivatives and pharmaceutical compositions containing the same
HUP0400155A3 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
AU2002238855A1 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
HUP0302193A3 (en) 1,4-diazabicyclo[3.2.2]nonabenzoxazole, -benzothiazole and benzimidazole derivatives, preparation thereof and pharmaceutical compositions containing them
AU2002309038A1 (en) Compositions for transmucosal administration containing coenzyme Q as the active ingredient
ZA200007415B (en) Amino acid derivatives and drugs containing the same as the active ingredient.
AU6309698A (en) Drugs containing aminopyridine derivatives as the active ingredient
MXPA03009206A (es) FORMULACIONES DE 3,7-DIAZABICICLO [3.3.1] COMO COMPUESTOS ANTIARRiTMICOS.
AU2001277738A1 (en) Piperidine derivatives and drugs containing these derivatives as the active ingredient
AU4431400A (en) Anticancer agents containing ep1 antagonists as the active ingredient
AU1650501A (en) 1,3,4-oxadiazoline derivatives and drugs containing these derivatives as the active ingredient
ZA200203311B (en) Pharmaceutical carrier formulation.
AU1556601A (en) 1,3,4-oxadiazolin-2-one derivatives and drugs containing these derivatives as the active ingredient